EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance

Misi Gu, Wenyu Wu, Jie You, Qianjun Wu, Fei Huang, Yixuan Zhang, Peng Wang, Dong Xi, Weiming Yan, Xiaojing Wang, Tao Chen iD, Di Wu iD und 2 weitere

Alimentary Pharmacology & Therapeutics · 2025

DOI: 10.1111/apt.70270 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2025. Verfasst von Misi Gu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease,…. Hauptthemen laut MEDLINE: Hepatitis B Surface Antigens, Antiviral Agents, Hepatitis B, Chronic, Hepatitis B virus. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The profiles of hepatitis B virus (HBV) integration related to hepatitis B surface antigen (HBsAg) loss remain largely unknown.

Aims

We aimed to delineate the patterns of HBV integration in virally suppressed chronic hepatitis B (CHB) patients and their association with HBsAg loss following antiviral therapy.

Methods

Forty‐five patients with paired liver biopsies were randomly selected from the Anchor study for high‐throughput viral integration detection. The primary endpoint was HBsAg loss at Week 96. In Group II (pegylated interferon alpha‐2b & entecavir), 13 patients achieved HBsAg loss, whereas all patients in Group I (entecavir monotherapy) and 17 in Group II failed to achieve HBsAg loss.

Results

At baseline, the level of clonal expansion was positively correlated with the duration of nucleos(t)ide analogue (NUC) treatment, the alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, whereas no association was observed with the HBsAg, hepatitis B core‐related antigen (HBcrAg), HBV RNA or covalently closed circular DNA (cccDNA) levels. Patients with less than 28 breakpoint types achieved a significantly higher rate of HBsAg loss following Peg‐IFN‐based therapy at Week 48 and 96, compared to those with more than 28.

Conclusions

The duration of NUC treatment, as well as ALT and AST levels, were associated with the level of clonal expansion in virally‐suppressed patients. A lower number of breakpoint types at baseline may be related to a higher HBsAg loss rate following Peg‐IFN‐based treatment and serve as a useful marker in guiding treatment decision‐making (NCT02327416). Trial Registration The Anchor study is registered at ClinicalTrials.gov , NCT02327416

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B Surface AntigensAntiviral AgentsHepatitis B, ChronicHepatitis B virusHumansMaleFemaleMiddle AgedAdultInterferon-alphaGuanineRecombinant ProteinsDNA, ViralPolyethylene GlycolsInterferon alpha-2Treatment Outcome

Stichwörter der Autor:innen

HBsAgpeg‐IFNviral DNA integrationvirally‐suppressed CHB

Substanzen

Hepatitis B Surface AntigensAntiviral AgentsInterferon-alphaentecavirGuanineRecombinant ProteinsDNA, Viralpeginterferon alfa-2bPolyethylene GlycolsInterferon alpha-2

Autor:innen und Institutionen

  • Department of Infectious Diseases, Tongji Medical College and State Key Laboratory for Diagnosis and Treatment of Severe Zoonotic Infectious Disease, Tongji Hospital, Huazhong University of Science and Technology, Wuhan…

ORCID-Profile: Tao Chen, Di Wu, Qin Ning, Meifang Han

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China

Zitieren

APA

Gu, M., Wu, W., You, J., Wu, Q., Huang, F., Zhang, Y., Wang, P., Xi, D., Yan, W., Wang, X., Chen, T., Wu, D., Ning, Q., & Han, M. (2025). High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70270

Vancouver

Gu M, Wu W, You J, Wu Q, Huang F, Zhang Y, et al. High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance. Alimentary Pharmacology & Therapeutics. 2025. doi:10.1111/apt.70270

BibTeX
@article{Gu2025,
  author = {Gu, Misi and Wu, Wenyu and You, Jie and Wu, Qianjun and Huang, Fei and Zhang, Yixuan and Wang, Peng and Xi, Dong and Yan, Weiming and Wang, Xiaojing and Chen, Tao and Wu, Di and Ning, Qin and Han, Meifang},
  title = {High‐Throughput Viral Integration Detection Reveals Baseline Breakpoints Burden Associated With HBsAg Seroclearance},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2025},
  doi = {10.1111/apt.70270}
}
Kostenlos starten →